Spontaneous remyelination occurs in experimental models of demyelination and in patients with multiple sclerosis, although to a limited extent. This enables the search for factors that promote remyelination. Using the Theiler's virus model of central nervous system demyelination, promotion of remyelination was observed after passive transfer of CNS-specific antiserum and transfer of CNS-specific purified immunoglobulin. Mouse polyclonal inmunoglobulin from normal non-syngeneic mice, comparable with the human inmunoglobulin preparation, also promotes CNS remyelination in the Theiler's virus model of multiple sclerosis. These experimental findings further bridge the gap with a pilot study that suggests clinical improvement after polyclonal immunoglobulin administration, possibly due to remyelination, in some multiple sclerosis patients with stable, steroid-unresponsive optic neuritis. In view of these experimental and clinical data, the physiological role of myelin in demyelination and remyelination is discussed, and the role of IgG solely as a deleterious molecule in the pathophysiology of multiple sclerosis and experimental demyelination is addressed.
Disability in multiple sclerosis (MS) results from a focal inflammatory and demyelinating process and the subsequent failure of full repair. Accordingly, treatments for MS may aim to: (1) limit inflammation and demyelination; (2) improve conduction in demyelinated fibres; (3) enhance myelin repair, that is, remyelination, and (4) prevent secondary axonopathy, that is, axon loss due to demyelination. Current treatment strategies in MS have focussed almost exclusively on number 1, the initial stage of the disease, by tending to limit inflammation and demyelination.' In our paper we focus mainly on strategy number 3, a novel treatment approach to enhance myelin repair by factors of the humoral immune system, especially exogenous immunoglobulin (IVIg).* Until recently, only a few studies testing IVIg treatment in MS were available, although the first reports were published in 1963. 23 This may be due to the conventional wisdom that assumes that immunoglobulins play a pathogenic role in the attack on myelin, based almost exclusively on increased intrathecal immunoglobulin production being a hallmark in the diagnosis of MS. Recently, there has been a renewed interest in IVIg treatment in MS.49 All except one of these studies are uncontrolled, and suggest a possible benefit in preventing and limiting the initial damage in MS. In contrast to slowing disease progression, one report focussed on the potential role of IVIg in clinical improvement possibly due to myelin repair.8
Remyelination
The traditional concept that repair in the CNS occurs rarely, if ever, seems outdated, at least for myelin. Spontaneous remyelination has now been described in toxin-induced, autoimmune, and viral-mediated models of CNS demyelination,'0 and in humans with MS."1-"3 Accordingly, a CNS demyelinating disease like MS is no longer conceived simply as a static and irreversible condition of myelin loss,'4 but as a dynamic equilibrium between demyelinating and remyelinating factors. This enables the search for factors that can improve the incomplete process of spontaneous remyelination in MS, and that can shift the equilibrium toward remyelination.
Immunoglobulin, IVIg spontaneous remyelination22-24 and for antibody-mediated remyelination," which suggests clinical improvement by remyelination. The possible role of IVIg in restoring clinical function and promoting CNS remyelination needs to be confirmed with a larger, controlled trial. This pilot study was performed to determine if a more extended controlled and "blinded" study would be worthwhile. A controlled trial testing immunoglobulin in MS patients with severe functional neurological deficits is approved and underway at the Mayo Clinic.
Pooled immunoglobulins from normal non-syngeneic mice promotes CNS remyelination in the Theiler's model of MS To further bridge the gap between the experimental studies and this pilot study on IVIg in chronic optic neuritis, we studied the effect of commercially available polyclonal IgG (Sigma Co, St Louis, MO) prepared from nonsyngeneic donor mice on TMEV-induced demyelination in SJL/J mice. The effect on remyelination by this product (dose 0-1 mg each week over five weeks administered intravenously) which is analogous to the human IVIg preparation, was measured by quantitative morphometry as described earlier. 20 We propose that there is a broader repertoire of antibodies (some with remyelinating potential) in the pooled polyclonal IgG from normal mice than in the laboratory-prepared IgG from the inbred strain of SJJ mice.
In conclusion, these data show that polyclonal, commercially-available mouse immunoglobulin from non-syngeneic mice promotes Promotion of remyelination by polyclonal immunoglobulin in Theiler's virus-induced demyelination and in multiple sclerosis remyelination in a viral model of MS. These findings increase the likelihood that human IVIg (non-syngeneic with multiple specificities) may also promote remyelination in human demyelinating diseases like MS.
The physiological role of myelin in demyelination and remyelination If factors in the humoral immune system are shown to induce remyelination in MS and experimental models of demyelination, the question remains whether remyelination is necessary and sufficient for clinical recovery. Is there a one-to-one relationship between myelin and clinical symptoms? Does loss of myelin cause clinical symptoms, and does repair of myelin reduce them?
In MS, many demyelinating lesions observed by MRI and by pathological analysis remain asymptomatic early in the course of the disease. Later in the disease course there is no clear correlation between clinical symptoms and MRI abnormalities.27 If demyelination is necessary and sufficient for the development of clinical deficits in MS, then it has been inferred that the absence of neurological deficits in patients with multiple MRI lesions is the result of strategically-placed lesions in clinically "silent" areas of the CNS. Another possible explanation is that demyelination is not sufficient to cause disease.
Compared with TMEV infection of immunocompetent SJIJJ mice which shows both CNS demyelination and inflammation, the toxic model of lysolecithin which induces a relatively pure demyelinated lesion without inflammation, does not produce observable clinical symptoms in the mouse. Admittedly, this lesion is usually relatively small, but can be strategically-placed. In addition, TMEV infection of mice that have the I2-microglobulin gene disrupted, and therefore do not express MHC class I molecules or CD8 + T cells,28 indicates that demyelination is necessary but not sufficient for the development of neurological deficits. TMEV-infected fl2 mutant mice develop, in contrast to other susceptible strains of mice, prominent multifocal histological demyelination without significant lymphocytic inflammatory responses and without clinical signs. This suggests that in the absence of inflammation, or at least a significant alteration in the extracellular milieu, demyelination is not sufficient to produce clinical symptoms. Therefore, the isolated pathophysiological role of myelin in demyelinating disease must be reconsidered.
The significance of IVIg administration for the concepts "inumunoglobulin" and "myelin" The clinical and laboratory experiments to enhance remyelination with IVIg administration enables us to question two fundamental concepts: (1) the role of immunoglobulin in MS, and (2) the physiological role of myelin in conditions of demyelination and remyelination.
The concept "immunoglobulin" in MS The availability, suggested therapeutic efficacy, and safety of IVIg treatment in humans, and the antibody-mediated remyelination in experimental animals has encouraged clinicians and immunologists to reassess the role of immunoglobulin in autoimmune diseases.8 9 19 29 30 The specificity of the oligoclonal immunoglobulin in cerebrospinal fluid and MS lesions remains undetermined; their pathogenicity has not been proved despite extensive investigation. 31 
